Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.

Autor: Rugo HS; Department of Medicine (Hematology/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA. Electronic address: hope.rugo@ucsf.edu., Oliveira M; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona; Breast Cancer Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Howell SJ; Breast Oncology, Division of Cancer Sciences, The University of Manchester, Manchester; The Christie NHS Foundation Trust, Manchester, UK., Dalenc F; Institut Claudius Regaud, Institut Universitaire du Cancer-Oncopole, Toulouse, France., Cortes J; Oncology Department, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona; Medica Scientia Innovation Research (MedSIR), Barcelona; Department of Medicine, Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Madrid, Spain., Gomez HL; Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima; Institute of Investigations in Biomedical Sciences, Universidad Ricardo Palma, Lima, Peru., Hu X; Shanghai Cancer Center, Fudan University, Shanghai, China., Jhaveri KL; Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York, USA., Krivorotko P; Petrov Research Institute of Oncology, Saint Petersburg, Russia., Loibl S; GBG Forschungs GmbH, Neu-Isenburg; Centre for Haematology and Oncology, Bethanien, Frankfurt, Germany., Morales Murillo S; Institut de Recerca Biomèdica, Barcelona, Spain., Nowecki Z; The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland., Okera M; ICON Cancer Centre, Adelaide, Australia., Park YH; Sungkyunkwan University School of Medicine, Samsung Medical Centre, Seoul., Sohn J; Yonsei University College of Medicine-Yonsei Cancer Center, Seoul, Republic of Korea., Toi M; Kyoto University Hospital, Kyoto., Iwata H; Aichi Cancer Center Hospital, Nagoya, Japan., Yousef S; Emek Medical Center, Afula, Israel., Zhukova L; Loginov Moscow Clinical Scientific Center, Moscow, Russia., Logan J; Oncology R&D, AstraZeneca, Cambridge, UK., Twomey K; Oncology R&D, AstraZeneca, Cambridge, UK., Khatun M; Oncology R&D, AstraZeneca, Cambridge, UK., D'Cruz CM; Oncology R&D, AstraZeneca, Waltham, USA., Turner NC; Royal Marsden Hospital, Institute of Cancer Research, London, UK.

Publikováno v: ESMO open [ESMO Open] 2024 Sep; Vol. 9 (9), pp. 103697. Date of Electronic Publication: 2024 Sep 05.

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK).

Autor: Huang, Xueqin¹ (AUTHOR), You, Li² (AUTHOR), Nepovimova, Eugenie³ (AUTHOR), Psotka, Miroslav^3,4 (AUTHOR), Malinak, David^3,4 (AUTHOR), Valko, Marian⁵ (AUTHOR), Sivak, Ladislav⁶ (AUTHOR), Korabecny, Jan⁴ (AUTHOR), Heger, Zbynek⁶ (AUTHOR), Adam, Vojtech⁶ (AUTHOR), Wu, Qinghua^1,3 (AUTHOR) wqh212@hotmail.com, Kuca, Kamil^3,4 (AUTHOR) kamil.kuca@uhk.cz

Publikováno v: Journal of Enzyme Inhibition & Medicinal Chemistry. Dec2023, Vol. 38 Issue 1, p1-29. 29p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.

Autor: Ladd B; Oncology iMed, AstraZeneca, Gatehouse Park, Waltham, MA, USA., Mazzola AM; Oncology iMed, AstraZeneca, Gatehouse Park, Waltham, MA, USA., Bihani T; Oncology iMed, AstraZeneca, Gatehouse Park, Waltham, MA, USA., Lai Z; Oncology iMed, AstraZeneca, Gatehouse Park, Waltham, MA, USA., Bradford J; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, UK., Collins M; Oncology iMed, AstraZeneca, Gatehouse Park, Waltham, MA, USA., Barry E; Oncology iMed, AstraZeneca, Gatehouse Park, Waltham, MA, USA., Goeppert AU; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, UK., Weir HM; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, UK., Hearne K; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, UK., Renshaw JG; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, UK., Mohseni M; Oncology iMed, AstraZeneca, Gatehouse Park, Waltham, MA, USA., Hurt E; Oncology, Medimmune, Gaithersburg, MD, USA., Jalla S; Oncology, Medimmune, Gaithersburg, MD, USA., Bao H; Oncology, Medimmune, Gaithersburg, MD, USA., Hollingsworth R; Oncology, Medimmune, Gaithersburg, MD, USA., Reimer C; Oncology iMed, AstraZeneca, Gatehouse Park, Waltham, MA, USA., Zinda M; Oncology iMed, AstraZeneca, Gatehouse Park, Waltham, MA, USA., Fawell S; Oncology iMed, AstraZeneca, Gatehouse Park, Waltham, MA, USA., D'Cruz CM; Oncology iMed, AstraZeneca, Gatehouse Park, Waltham, MA, USA.

Publikováno v: Oncotarget [Oncotarget] 2016 Aug 23; Vol. 7 (34), pp. 54120-54136.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.